Adults living with asthma face a significantly higher risk of developing invasive pneumococcal disease compared to those without the condition, according to a recent study published in the American Journal of Preventive Medicine. The research, conducted by investigators at the Centers for Disease Control and Prevention (CDC), highlights a critical gap in vaccine uptake among this vulnerable population. Despite clear clinical guidelines recommending pneumococcal vaccination for adults with asthma, many remain unprotected against Streptococcus pneumoniae, a bacterium capable of causing pneumonia, meningitis, and bloodstream infections.
Risk Factors for Pneumococcal Disease in Asthma Patients
The CDC study underscores that asthma is an independent risk factor for pneumococcal disease. Chronic airway inflammation and the frequent use of inhaled corticosteroids—standard treatments for asthma management—can alter the local immune environment in the lungs. This environment may facilitate the colonization and invasion of pneumococcal bacteria.
According to the CDC’s Advisory Committee on Immunization Practices (ACIP), the risk is not uniform across all age groups. However, the physiological impact of asthma on respiratory health creates a heightened vulnerability that persists even when the condition is well-controlled. Unlike healthy adults, those with asthma are more likely to experience severe complications if they contract a vaccine-preventable respiratory infection.
Vaccine Recommendations and Clinical Guidance
Current CDC guidelines advise that adults aged 19 through 64 with underlying medical conditions, including asthma, should receive pneumococcal vaccination. The specific vaccine schedule depends on an individual’s age and their history of previous vaccinations.
Clinicians typically use one of two primary options:
- PCV20 (Prevnar 20): A single dose that provides protection against 20 serotypes of the bacteria.
- PCV15 (Vaxneuvance): A dose followed by a dose of PPSV23 (Pneumovax 23) if the patient has not previously received pneumococcal conjugate vaccines.
Patients are encouraged to consult their primary care provider or an asthma specialist to review their immunization records. Because asthma management often involves ongoing communication with healthcare teams, these visits serve as a primary opportunity to verify if a patient is up to date on their pneumococcal series.
Addressing the Vaccination Gap
The findings from the American Journal of Preventive Medicine serve as a call to action for both patients and healthcare providers. While asthma is widely recognized as a respiratory condition, the intersection of immunology and lung health is often overlooked during routine checkups.
The CDC emphasizes that vaccination is a preventive measure that reduces the burden of disease and the risk of hospitalization. Patients who have been diagnosed with asthma should proactively ask their physician about their pneumococcal vaccination status. By closing this gap, adults with asthma can significantly lower their risk of severe illness, ensuring that their underlying respiratory condition does not become a gateway for more serious, systemic bacterial infections.
Frequently Asked Questions
Why is the pneumococcal vaccine recommended for people with asthma?
Asthma causes chronic inflammation in the airways, which can make the lungs more susceptible to infections like Streptococcus pneumoniae. Vaccination provides necessary immune protection that the body may not provide on its own.
Does the flu shot protect against pneumococcal disease?
No. The influenza vaccine protects against the flu virus, while pneumococcal vaccines protect against the Streptococcus pneumoniae bacteria. Both are important for adults with asthma, as the flu can sometimes lead to secondary bacterial pneumonia.
If I have asthma, how many doses do I need?
The number of doses depends on which vaccine you receive and your vaccination history. You should discuss your specific needs with your healthcare provider to ensure you follow the current CDC immunization schedule.
Worth a look